[Form 4] Lexeo Therapeutics, Inc. Insider Trading Activity

Lexeo Therapeutics’ Chief Medical Officer Narinder Pal Bhalla received new equity awards in the form of stock options and restricted stock units.

Rhea-AI Filing Summary

Lexeo Therapeutics’ Chief Medical Officer Narinder Pal Bhalla received new equity awards in the form of stock options and restricted stock units. On February 13, 2026, he was granted 297,000 stock options with a $6.31 exercise price and 49,500 RSUs, both at no cash cost to him.

The option grant vests with 25% of the underlying shares becoming exercisable on January 20, 2027, and the remaining 75% vesting in equal monthly installments over the following three years, contingent on continuous service. The RSUs vest 25% on February 15, 2027, with the rest vesting in equal quarterly installments thereafter, also subject to continued service.

Insider Trade Summary

Grant/Award: 346,500 shares

Grant/Award 2 txns

Insider Bhalla Narinder Pal

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	297,000	$0.00	$0.00
Grant/Award	Common Stock	49,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 297,000 contracts (Direct); Common Stock — 49,500 shares (Direct)

Footnotes (3)

1. F1. The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2027, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date.
2. F2. Includes 49,500 RSUs.
3. F3. 25% of the shares underlying the option vest and become exercisable on January 20, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LXEO’s Chief Medical Officer report on this Form 4?

Lexeo Therapeutics’ Chief Medical Officer Narinder Pal Bhalla reported receiving equity awards. He was granted 297,000 stock options at a $6.31 exercise price and 49,500 restricted stock units, both effective February 13, 2026, as part of his compensation package.

How many stock options were granted to Narinder Pal Bhalla at Lexeo Therapeutics (LXEO)?

Narinder Pal Bhalla received 297,000 stock options. These options carry a $6.31 exercise price and vest over time, with 25% becoming exercisable on January 20, 2027 and the remaining shares vesting in equal monthly installments, subject to his continuous service.

What restricted stock unit (RSU) grant did LXEO’s Chief Medical Officer receive?

He received 49,500 RSUs, each representing one share of Lexeo Therapeutics common stock. Twenty-five percent vest on February 15, 2027, and the remaining RSUs vest in equal quarterly installments thereafter, conditioned on his continued service with the company.

Are the equity awards to LXEO’s Chief Medical Officer open-market purchases or compensation grants?

The reported transactions are compensation grants, not open-market trades. Both the 297,000 stock options and 49,500 RSUs were acquired at a price of $0 per share, consistent with awards granted under an equity incentive or similar compensation plan.

How do the stock options granted to LXEO’s Chief Medical Officer vest over time?

The stock options vest on a service-based schedule. Twenty-five percent of the underlying shares vest and become exercisable on January 20, 2027, while the remaining 75% vest in equal monthly installments thereafter, contingent on his continuous service with Lexeo Therapeutics.

What is the vesting schedule for the RSUs granted to Narinder Pal Bhalla at LXEO?

The RSUs vest gradually based on continued employment. Twenty-five percent of the 49,500 RSUs vest on February 15, 2027. The remaining RSUs then vest in equal quarterly installments on Lexeo’s standard quarterly vesting dates, assuming he remains in service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 04:55 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bhalla Narinder Pal

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, 6TH FLOOR

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		A		49,500(1)	A	$0	49,500(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$6.31	02/13/2026		A		297,000		(3)	02/12/2036	Common Stock	297,000	$0	297,000	D

Explanation of Responses:

1. The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2027, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date.

2. Includes 49,500 RSUs.

3. 25% of the shares underlying the option vest and become exercisable on January 20, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.

	/s/ Carole Rosenberg, Attorney-in-Fact	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.